Skip to content

ROLE OF SIMILLIMUM IN THE MANAGEMENT OF ATTENTION DEFICIT HYPERACTIVE DISORDER IN SCHOOL CHILDREN UP TO 12 YEARS

A Clinical Study on role of Simillimum in the management of Attention Deficit Hyperactive Disorder in School children upto 12 years. - Nil

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/11/037884
Enrollment
100
Registered
2021-11-09
Start date
Unknown
Completion date
Unknown
Last updated
2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F902- Attention-deficit hyperactivity disorder, combined type Health Condition 2: F901- Attention-deficit hyperactivity disorder, predominantly hyperactive type Health Condition 3: F900- Attention-deficit hyperactivity disorder, predominantly inattentive type

Interventions

Intervention1: Homeopathic medicine: Homeopathic medicine selected on the basis of similarity Dose- 200 centismal scale potency one globule of 30 size medicated globule Frequency - one dose once in

Sponsors

Dr Siju V
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Children diagnosed with ADHD. Children between 6 to 12 years of age.

Exclusion criteria

Exclusion criteria: Children undergoing any other chronic treatment

Design outcomes

Primary

MeasureTime frame
Common Simillimum suited for the management of ADHD can be identified. 200th potency of simillimum is useful for ADHD.Timepoint: first 6 moths recruiting extended for another 6 months if required last one year followup assessment and analysis, report preparation

Secondary

MeasureTime frame
Common type of ADHD prevalent in schools of Kanniyakumari Dist. will be identified.Timepoint: first 6 moths recruiting extended for another 6 months if required last one year followup assessment and analysis, report preparation

Countries

India

Contacts

Public ContactSIJU V

sarada krishna homoeopathic medical college

drmmuruganhomoeo@gmail.com9443343707

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026